Merck 3Q Net Profit, Revenue Rose
14 Novembro 2019 - 3:51AM
Dow Jones News
By Carlo Martuscelli
Merck KGaA (MRK.XE) said Thursday that net profit for the third
quarter increased marginally, while an increase in revenue was
supported by the health-care and life-science divisions.
The Germany pharmaceuticals and chemicals company made a profit
of 343 million euros ($378.3 million) in the period, from EUR340
million the previous year. Net sales climbed 8.1% to EUR4.05
billion. On an organic basis net sales grew 5.7%.
Revenue from the health-care business increased 10%, helped by
sales of its Mavenclad treatment as well as high demand for
medicines in China. Life sciences earnings grew 12%.
The closely watched company metric Ebitda pre--or earnings
before interest, taxes, depreciation and amortization before
one-time items--totaled EUR1.11 billion, up from EUR963 million
last year.
Merck said it now expects to report overall sales of between
EUR15.7 billion and EUR16.3 billion for 2019, from between EUR15.3
billion and EUR15.9 billion. It cited the acquisition of Versum as
driving the upgrade.
It continued to expect organic revenue growth of 3%-5% for the
year. The company said it forecasts Versum to contribute EUR80
million-EUR90 million to Ebitda pre.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
November 14, 2019 01:36 ET (06:36 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Merck KGAA (TG:MRK)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Merck KGAA (TG:MRK)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024